LATEST NEWS
Phase I trial results of SG2000 (SJG-136)Wed 4th Jun 08
The phase I trial results of Spirogen's SG2000 (SJG-136) will be presented at ASCO: Abstract ID:
LATEST PRESS RELEASE
Paris (France) and London (United Kingdom)Mon 2nd Jun 08
Ipsen and Spirogen's SJG-136 shows encouraging results in the treatment of refractory solid tumours
SECURE AREA
A clinical stage Biotechnology company creating potent small molecules based on novel mechanisms and modern chemistry to target important cancers and infectious diseases.
The company has significant experience utilizing cutting edge technologies to make effective DNA sequence targeted agents.
